Business
Investors in drugmaker Mesoblast sweat on crucial capital raising – Sydney Morning Herald
The stem cell giant says it needs cash from its existing partnerships to ‘continue as a going concern’.
The ability of the group to continue as a going concern and realise its assets and discharge its liabilities in the normal course of business are dependent on cash inflows from successfully completing the private placement, as well as from existing strategic and financing partnerships, the auditors report said.
Analysts at Bell Potter noted last month that Mesoblasts balance sheet could come under pressure in the 2022 financial year if there were any hiccups with agreements and payments from partners…
-
Business21 hours agoThe ultimate Australian stocks to buy and hold for 10+ years
-
Noosa News21 hours agoNew process turns wheat straw and oat husks into sustainable clothing
-
Noosa News17 hours agoSouthern NSW farmers call for financial relief as ongoing drought takes a toll
-
Noosa News16 hours agoLNP Premier David Crisafulli announces ‘Queensland’s royal commission’ into CFMEU